营收情况 - Absci Corporation在2024年第一季度的营收为0.9百万美元，较去年同期的1.3百万美元有所下降[12] 研发支出 - 研发支出为2024年第一季度的12.2百万美元，较去年同期的12.7百万美元有所下降，主要是由于人员成本降低，但股票补偿费用增加[13] 销售和管理费用 - 销售、一般和管理费用为2024年第一季度的8.7百万美元，较去年同期的9.6百万美元有所下降，主要是由于人员成本降低和行政成本持续减少，但股票补偿费用增加[14] 净亏损 - 净亏损为2024年第一季度的22.0百万美元，较去年同期的23.4百万美元有所下降[15] 现金及投资情况 - 截至2024年3月31日，现金、现金等价物和短期投资为1.615亿美元，较去年12月31日的9770万美元有所增加[16]

Absci Corporation (ABSI) is scheduled to report first-quarter 2024 results on May 14.Let's see how things might have shaped up prior to the announcement.Factors to ConsiderAbsci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients.The company primarily generates revenues from drug-creation activities. ABSI is still early in the adoption phase of its drug creation model.Hence, investors will mostly focus on pipeline up ...

Absci Corporation (ABSI) shares rallied 16.8% in the last trading session to close at $6.59. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20% gain over the past four weeks.The sudden rise in the share price can be attributed to the positive investor mindset regarding the potential of Absci's preclinical pipeline. Notably, in February 2024, the company initiated IND-enabling studies for ABS-101, an anti-TL1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-3383487 (State or oth ...

Exhibit 99.1 Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 – Absci Corporation (Nasdaq: ABSI), a data-first generativ ...

Viva Biotech的投资组合公司AceLink Therapeutics - AL01211在健康志愿者中的Phase 1临床试验数据发布[2] Basking Biosciences - 完成了5500万美元融资，用于加速BB-031的临床开发[5] Technoderma Medicines - 成功完成了多百万美元的Pre-B轮融资[7] - TDM-105795的临床试验取得了成功[7] - TDM-180935的临床试验取得了成功[7]

VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proce ...

Absci Corporation (ABSI) shares rallied 10% in the last trading session to close at $5.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 18.4% gain over the past four weeks.Last month, the company initiated IND-enabling studies for ABS-101, an anti-TL1A antibody developed using its de novo generative AI foundation model. This might have been driving the share price rally.This company is expected to post qua ...

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and cond ...

公开发行 - Absci公司宣布启动了7500万美元普通股的公开发行[1] - Absci打算利用此次发行的净收益用于内部资产项目的发展[2] - Absci公司将根据之前在美国证券交易委员会（SEC）提交的有效的S-3表格（文件号333-267043）进行发行[4] 主承销商 - Morgan Stanley和TD Cowen将作为拟议发行的联合主承销商[3]